Allogenic human umbilical cord derived mesenchymal stem cell (Beike Biotechnology)

人脐带间充质干细胞（北科生物）

Report date: 2026/02/11 20:01:36

Base Information

Drug NameAllogenic human umbilical cord derived mesenchymal stem cell (Beike Biotechnology)
Drug Alias NameUC-MSCTUC-MSC (Beike Biotechnology)Human umbilical cord mesenchymal stem cells (hUC-MSC) - Beike BiotechnologyWharton's Jelly-derived mesenchymal stem cells (WJMSC) - Beike Biotechnology
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsLupus Erythematosus, SystemicMyocardial InfarctionPrimary Ovarian Insufficiency +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Beike Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen Beike Biotechnology Co Ltd
Inactive CompaniesNanjing Medical University
Active IndicationsLupus Erythematosus, SystemicMyocardial InfarctionSpinocerebellar Degenerations +[7] 
Inactive IndicationsPrimary Ovarian InsufficiencyAnus Diseases

Other Information

ATC CodeN/A
Related LinksN/A